Incobotulinumtoxina - Biologic Drug Details

Summary for incobotulinumtoxina

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for incobotulinumtoxina

Recent Clinical Trials for incobotulinumtoxina

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Walter Reed National Military Medical Center	Phase 2
Merz Aesthetics GmbH	Phase 2
University of Minnesota	Phase 2

See all incobotulinumtoxina clinical trials

Pharmacology for incobotulinumtoxina

Mechanism of Action	Acetylcholine Release Inhibitors
Physiological Effect	Neuromuscular Blockade
Established Pharmacologic Class	Acetylcholine Release Inhibitor Neuromuscular Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for incobotulinumtoxina Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for incobotulinumtoxina Derived from Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	10,653,754	2038-01-26	Company disclosures
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	10,709,772	2038-09-12	Company disclosures
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	10,921,312	2034-02-19	Company disclosures
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	11,529,398		Company disclosures
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	7,927,836	2025-06-17	Company disclosures
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	9,217,172	2032-09-28	Company disclosures

3) Low Certainty: US Patents for incobotulinumtoxina Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	10,016,338	2033-03-11	Patent claims search
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	10,406,213	2030-03-30	Patent claims search
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	10,577,154	2029-05-13	Patent claims search
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	10,729,751	2031-03-30	Patent claims search
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	10,912,714	2038-07-09	Patent claims search
Merz Pharmaceuticals Gmbh C/o Merz Pharmaceuticals Llc	XEOMIN	incobotulinumtoxina	For Injection	125360	11,033,610	2039-09-09	Patent claims search

Botulinum Toxin Market Dynamics and Financial Trajectory: A Comprehensive Overview

Introduction

The botulinum toxin market, which includes products like incobotulinumtoxina, is experiencing significant growth driven by its expanding applications in both therapeutic and aesthetic domains. Here, we delve into the market dynamics, financial projections, and key factors influencing the growth of this biologic drug.

Market Size and Growth Projections

The global botulinum toxin market is anticipated to grow substantially over the next decade. By 2032, the market is expected to reach approximately USD 13.4 billion, up from USD 6.6 billion in 2023, with a compound annual growth rate (CAGR) of 8.4% during the forecast period[1][3][4].

Regional Dominance

North America currently holds the largest market share, accounting for over 39.0% of the revenue in 2022, with a significant portion of this attributed to the high demand for cosmetic procedures and the presence of major market players like AbbVie and Ipsen Pharma[1][3][4].

Asia-Pacific: The Emerging Market

The Asia-Pacific region is forecasted to experience the fastest CAGR during the forecast period, driven by a growing demand for cosmetic procedures, favorable reimbursement policies, and the increasing availability of advanced healthcare facilities in countries like South Korea, China, and Japan[1][4][5].

Product Type and Applications

Type A Segment

The type A segment, which includes products like BOTOX (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA), holds the largest market share and is expected to continue growing significantly over the forecast period. Incobotulinumtoxina, another type A botulinum toxin, is also gaining traction due to its efficacy and safety profile[1][3][5].

Therapeutic and Aesthetic Applications

The therapeutic segment dominates the market, with applications including the treatment of chronic migraines, muscle spasticity, eye disorders, overactive bladders, and excessive sweating. Aesthetic applications, such as reducing facial wrinkles and fine lines, also contribute significantly to the market growth[1][3][5].

Key Players and Market Strategies

AbbVie Inc.

AbbVie, through its acquisition of Allergan, has strengthened its position in the market with BOTOX, a leading botulinum toxin product. The company's strategic marketing efforts and expansion of BOTOX for various therapeutic uses have solidified its market leadership[1].

Ipsen Pharma

Ipsen Pharma's product Dysport has a substantial global presence, registered in over 85 countries. The company's robust R&D and strategic partnerships have enabled it to innovate and enhance its product portfolio, contributing to its strong market position[1].

Other Key Players

Other notable players in the market include Merz Pharma, Medytox, Galderma, Revance Therapeutics, and US WorldMeds, LLC. These companies are investing heavily in R&D and strategic initiatives such as mergers and acquisitions to expand their market share[2][4][5].

Market Dynamics and Growth Drivers

Increasing Demand for Cosmetic Procedures

The rising demand for non-invasive cosmetic procedures is a significant driver of the botulinum toxin market. Women, who constitute about 92% of all treatments, are driving this trend, especially in the 40-54 age group[5].

Therapeutic Applications

The expansion of therapeutic applications, including treatments for chronic conditions like migraines and muscle spasticity, is also driving market growth. Regulatory approvals and innovative research are further contributing to this trend[1][3][5].

Strategic Mergers and Acquisitions

Strategic mergers and acquisitions, such as AbbVie’s acquisition of ImmunoGen, are enhancing the industry’s commitment to broadening therapeutic applications and improving patient care through advanced treatments[1].

Regulatory and Reimbursement Trends

Improving reimbursement policies and regulatory milestones are also propelling the market forward. The inclusion of botulinum toxin injections in reimbursement policies has increased patient affordability and access to these treatments[5].

Financial Trajectory

Revenue Projections

The market is projected to grow from USD 6.6 billion in 2023 to USD 13.4 billion by 2032, with annual growth rates indicating a steady increase:

• 2023: USD 6.6 billion
• 2024: USD 7.1 billion
• 2025: USD 7.8 billion
• 2026: USD 8.6 billion
• 2027: USD 9.2 billion
• 2028: USD 9.7 billion
• 2029: USD 10.5 billion
• 2030: USD 11.3 billion
• 2031: USD 12.2 billion
• 2032: USD 13.4 billion[1][3].

Conclusion

The botulinum toxin market, including products like incobotulinumtoxina, is poised for significant growth driven by its expanding therapeutic and aesthetic applications. With a projected CAGR of 8.4% from 2023 to 2032, the market is expected to reach USD 13.4 billion by 2032. Key drivers include increasing demand for cosmetic procedures, expanding therapeutic uses, strategic mergers and acquisitions, and favorable regulatory and reimbursement trends.

Key Takeaways

• Market Size: Expected to reach USD 13.4 billion by 2032.
• CAGR: 8.4% from 2023 to 2032.
• Regional Growth: Asia-Pacific region expected to grow at the fastest CAGR.
• Product Type: Type A segment dominates the market.
• Applications: Therapeutic segment holds the largest share, with significant aesthetic applications.
• Key Players: AbbVie, Ipsen Pharma, and other major pharmaceutical companies.

FAQs

1. What is the projected CAGR of the botulinum toxin market from 2023 to 2032?

   • The projected CAGR is 8.4% from 2023 to 2032[1][3].

2. Which region is expected to experience the fastest growth in the botulinum toxin market?

   • The Asia-Pacific region is expected to experience the fastest growth[1][4][5].

3. What are the primary applications of botulinum toxin?

   • The primary applications include therapeutic uses such as treating chronic migraines, muscle spasticity, and aesthetic uses like reducing facial wrinkles and fine lines[1][3][5].

4. Which companies are leading the botulinum toxin market?

   • Key players include AbbVie, Ipsen Pharma, Merz Pharma, Medytox, and others[1][2][4].

5. What is driving the growth of the botulinum toxin market?

   • Increasing demand for cosmetic procedures, expanding therapeutic applications, strategic mergers and acquisitions, and favorable regulatory and reimbursement trends are driving the market growth[1][3][5].

Sources

1. Market.us - Botulinum Toxin Market to Surge at 8.4% CAGR from 2023-2032[1].
2. IndustryARC - Botulinum Toxin Market - IndustryARC[2].
3. PharmiWeb - Botulinum Toxin Market Predicted USD 13.4 Billion By 2032, An Approximate 8.4% CAGR Growth[3].
4. Grand View Research - Botulinum Toxin Market Size, Share & Growth Report, 2030[4].
5. SkyQuest - Botulinum Toxin Market Size, Share, Growth Analysis, By Product Type[5].

Last updated: 2024-12-19